EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Safety and efficacy of a reduced frequency viral monitoring strategy for Epstein‐Barr virus, cytomegalovirus, and BK polyomavirus post‐kidney transplant: A quality assurance initiative

Christie Rampersad iD, William Kong, Chris Wiebe iD, Robert Balshaw, Jared Bullard, Armelle Perez Cortes Villalobos, Aaron Trachtenberg iD, James Shaw, Martin Karpinski, Peter W Nickerson iD, Julie Ho iD

Clinical Transplantation · 2024

DOI: 10.1111/ctr.15292 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Transplantation, 2024. Verfasst von Christie Rampersad und 10 weiteren Autor:innen. Beteiligte Einrichtung: University Health Network, University of Toronto, Toronto, Ontario, Canada. Hauptthemen laut MEDLINE: Kidney Transplantation, Epstein-Barr Virus Infections, BK Virus, Cytomegalovirus Infections. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: CIHR, Canadian Institutes of Health Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

There is variability in recommended viral monitoring protocols after kidney transplant. In response to increased demand for laboratory testing during the COVID‐19 pandemic, the Transplant Manitoba Adult Kidney Program updated its monitoring protocols for cytomegalovirus (CMV), Epstein‐Barr virus (EBV), and BK polyomavirus (BKV) to a reduced frequency.

Methods

This single‐center nested case‐control study evaluated 252 adult kidney transplant recipients transplanted from 2015 to 2021, with the updated protocols effective on March 19 th 2020. Cases included recipients transplanted after the protocol update who developed CMV, EBV, and BKV DNAemia and were matched to controls with DNAemia transplanted prior to the protocol update. The primary outcome was the difference in maximum DNA load titers between cases and matched controls. Secondary outcomes included time to initial DNAemia detection and DNAemia clearance. Safety outcomes of tissue‐invasive viral disease were described.

Results

There were 216 recipients transplanted preupdate and 36 recipients postupdate. There was no difference between cases and controls in maximum or first DNA load titers for EBV, CMV, or BKV. Cases experienced earlier EBV DNAemia detection (26 (IQR 8, 32) vs. 434 (IQR 96, 1184) days, p = .005). Median follow‐up was significantly longer for recipients transplanted preupdate (4.3 vs. 1.3 years, p < .0001). After adjusting for follow‐up time, there was no difference in DNAemia clearance or tissue‐invasive viral disease.

Conclusion

Our findings suggest that reduced frequency viral monitoring protocols may be safe and cost‐effective. This quality assurance initiative should be extended to detect longer‐term and tissue‐invasive disease outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Kidney TransplantationEpstein-Barr Virus InfectionsBK VirusCytomegalovirus InfectionsAdultHumansHerpesvirus 4, HumanCytomegalovirusCase-Control StudiesPandemicsDNADNA, ViralTransplant Recipients

Stichwörter der Autor:innen

BK polyomavirusEpstein‐Barr viruscytomegaloviruskidney transplant

Substanzen

DNADNA, Viral

Autor:innen und Institutionen

  • University Health Network, University of Toronto, Toronto, Ontario, Canada.
  • Department of Internal Medicine, University of Manitoba, Winnipeg, Manitoba, Canada.
  • Transplant Manitoba Adult Kidney Program, Winnipeg, Manitoba, Canada.
  • George and Fay Yee Centre for Healthcare Innovation, Winnipeg, Manitoba, Canada.
  • Cadham Provincial Laboratory, Winnipeg, Manitoba, Canada.
  • Department of Pediatrics, University of Manitoba, Winnipeg, Manitoba, Canada.

ORCID-Profile: Christie Rampersad, Chris Wiebe, Aaron Trachtenberg, Peter W Nickerson, Julie Ho

Förderung

  • CIHR
  • Canadian Institutes of Health Research

Zitieren

APA

Rampersad, C., Kong, W., Wiebe, C., Balshaw, R., Bullard, J., Villalobos, A. P. C., Trachtenberg, A., Shaw, J., Karpinski, M., Nickerson, P. W., & Ho, J. (2024). Safety and efficacy of a reduced frequency viral monitoring strategy for Epstein‐Barr virus, cytomegalovirus, and BK polyomavirus post‐kidney transplant: A quality assurance initiative. Clinical Transplantation. https://doi.org/10.1111/ctr.15292

Vancouver

Rampersad C, Kong W, Wiebe C, Balshaw R, Bullard J, Villalobos APC, et al. Safety and efficacy of a reduced frequency viral monitoring strategy for Epstein‐Barr virus, cytomegalovirus, and BK polyomavirus post‐kidney transplant: A quality assurance initiative. Clinical Transplantation. 2024. doi:10.1111/ctr.15292

BibTeX
@article{Rampersad2024,
  author = {Rampersad, Christie and Kong, William and Wiebe, Chris and Balshaw, Robert and Bullard, Jared and Villalobos, Armelle Perez Cortes and Trachtenberg, Aaron and Shaw, James and Karpinski, Martin and Nickerson, Peter W and Ho, Julie},
  title = {Safety and efficacy of a reduced frequency viral monitoring strategy for Epstein‐Barr virus, cytomegalovirus, and BK polyomavirus post‐kidney transplant: A quality assurance initiative},
  journal = {Clinical Transplantation},
  year = {2024},
  doi = {10.1111/ctr.15292}
}
Kostenlos starten →